Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate.
about
Novel agents for chronic lymphocytic leukemiaSafe handling of oral antineoplastic medications: focus on targeted therapeutics in the home settingProfile of bosutinib and its clinical potential in the treatment of chronic myeloid leukemiaEuropean LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemiaGenetic aberrations in imatinib-resistant dermatofibrosarcoma protuberans revealed by whole genome sequencingIntersection of cardiology and oncology clinical practices.Dasatinib inhibits site-specific tyrosine phosphorylation of androgen receptor by Ack1 and Src kinasesOnce-daily dasatinib for treatment of patients with chronic myeloid leukemia.Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemiaDasatinib enhances megakaryocyte differentiation but inhibits platelet formation.Dasatinib: a review of its use in the treatment of chronic myeloid leukaemia and Philadelphia chromosome-positive acute lymphoblastic leukaemia.Spontaneous subdural hematoma in a patient with Philadelphia chromosome-positive acute lymphoblastic leukemia with normal platelet count after dasatinib treatment.Gastrointestinal bleeding in a chronic myeloid leukaemia patient precipitated by dasatinib-induced platelet dysfunction: Case report.Predictors of primary imatinib resistance in chronic myelogenous leukemia are distinct from those in secondary imatinib resistance.High-risk childhood acute lymphoblastic leukemiaThe role of p27(Kip1) in dasatinib-enhanced paclitaxel cytotoxicity in human ovarian cancer cellsSafety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinibSTAT-Related Profiles Are Associated with Patient Response to Targeted Treatments in Locally Advanced SCCHN.Triple-negative breast cancer: new perspectives for targeted therapies.IL1RAP as a surface marker for leukemia stem cells is related to clinical phase of chronic myeloid leukemia patients.Pathway inhibition: emerging molecular targets for treating glioblastoma.Physiological, pharmacological and toxicological considerations of drug-induced structural cardiac injuryThe use of betaine HCl to enhance dasatinib absorption in healthy volunteers with rabeprazole-induced hypochlorhydria.Outcome of treatment of chronic myeloid leukemia with second-generation tyrosine kinase inhibitors after imatinib failureChronic myelogenous leukemia: role of stem cell transplant in the imatinib era.Interaction of innovative small molecule drugs used for cancer therapy with drug transporters.Dasatinib inhibits c-src phosphorylation and prevents the proliferation of Triple-Negative Breast Cancer (TNBC) cells which overexpress Syndecan-Binding Protein (SDCBP).Dasatinib - clinical trials and management of adverse events in imatinib resistant/intolerant chronic myeloid leukemiaManagement of imatinib-resistant patients with chronic myeloid leukemia.Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant gliomaSuboptimal response to or failure of imatinib treatment for chronic myeloid leukemia: what is the optimal strategy?Current status of therapy for chronic myeloid leukemia: a review of drug development.Dasatinib-induced haemorrhagic colitis in chronic myeloid leukaemia (CML) in blast crisis.Inhibition of Src family kinases with dasatinib blocks migration and invasion of human melanoma cells.Dasatinib in chronic myeloid leukemia: a review.Dasatinib: a potent SRC inhibitor in clinical development for the treatment of solid tumors.Tyrosine kinase inhibitors as initial therapy for patients with chronic myeloid leukemia in accelerated phase.Dasatinib in solid tumors.Pleural/pericardic effusions during dasatinib treatment: incidence, management and risk factors associated to their development.Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia.
P2860
Q21198858-4AC94330-5328-447A-BD2D-D8BF5FCA6DD0Q23923997-2D289932-6F08-477D-B11D-5C0DBB675150Q24607114-E2C3F8D5-84ED-48F5-AB93-EAAB8B3173B6Q26749324-92DF5B09-281E-46D5-AE2A-AA2DE0588A97Q28534967-90C4FD6F-C12E-44A7-BAD5-E72ACF88E2CAQ30428702-83DEFEC5-3C95-40FB-8EFF-DBAE094123F3Q30433918-8211733C-3AA9-49C9-9CAE-5529A38CB593Q33383954-1C86420A-0BDC-4F98-AE01-85548A412808Q33384361-6899DD0D-331C-4823-BCD5-3041EA77A6BEQ33394424-52D791A5-F26C-434F-AA79-E6C8BF1BEC78Q33397085-582F15EB-9941-4E15-8A2D-0FD24BCC9E3FQ33416438-E26FD640-4F8D-40DD-BEC7-5CB107661326Q33423255-B7675813-1BC6-4FD7-AB87-0509768F4701Q33561227-2934B481-A72C-465E-A7D9-AE67A1B44989Q33622837-4ECEE1D1-0DBC-4CC5-8782-48444076CCE9Q33980966-A4E9DFF9-DA1E-4903-B02C-BA50CE527A0BQ34210528-360416F2-0EC0-4D2A-A908-B8C690FC3255Q34518357-EB638D08-E1E6-44FC-B41A-3AF30225498DQ35001758-913F8CCD-F231-4132-A46B-5B83593C3854Q35016953-59309380-F0B0-453F-9024-79E5DEBDD81FQ35021359-1D1FB306-6424-4007-B864-0518EF149CFAQ35039202-2CDE5F09-C5A3-429F-ADA9-3614E800F30FQ35318395-9C00E5E6-C0C1-4CB7-8B0A-632EDAF54E45Q35596200-70D71473-655F-421E-9369-4037DE36FAB0Q35633858-45C65BF5-8ACF-4286-9FE3-7A1658972A01Q35708124-7E564498-6A0A-4669-8213-22C61C49D685Q36265028-19BE878C-2A35-4839-8524-8E0F9EC83E73Q36462473-2AEB4B9B-E14B-4FAA-9C62-E338836D1249Q36776423-BB302F71-E439-44C6-9A28-95CBC5BAE8F3Q36949546-1BF97209-F8C6-4E6B-9903-6514BF71C15EQ37148391-382C5EA7-3F63-4D2C-BFC5-3AA05B90A40AQ37179388-AF3287F5-0362-4E00-83AB-F3BD4950A048Q37391786-14B17822-0EBF-4B31-9658-CF93E2660507Q37401245-AF0F4350-CC16-4790-863D-7C04F5CC23B6Q37523302-B7A7E5B5-2D88-4951-A20D-F30E6F4140D2Q37613072-67F9A05F-3CC5-4074-9E0D-E7E821228124Q37647076-2B5057DF-38EC-41A8-BBC2-91E6868DE6B9Q37683766-D4FE7803-50C8-4779-B19A-654559CA9D55Q37781050-F5966228-3ED6-49B8-8F81-ABD4FD679AC9Q37791429-ED10368B-19FF-4F49-86D0-756FF336D886
P2860
Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Sprycel for chronic myeloid le ...... tolerant of imatinib mesylate.
@en
Sprycel for chronic myeloid le ...... tolerant of imatinib mesylate.
@nl
type
label
Sprycel for chronic myeloid le ...... tolerant of imatinib mesylate.
@en
Sprycel for chronic myeloid le ...... tolerant of imatinib mesylate.
@nl
prefLabel
Sprycel for chronic myeloid le ...... tolerant of imatinib mesylate.
@en
Sprycel for chronic myeloid le ...... tolerant of imatinib mesylate.
@nl
P2093
P921
P1476
Sprycel for chronic myeloid le ...... tolerant of imatinib mesylate.
@en
P2093
Angela Men
Ann Farrell
Brian Booth
Carol Noory
David Morse
Edvardas Kaminskas
Haleh Saber
Joga Gobburu
Julie Bullock
Leslie Kenna
P304
P356
10.1158/1078-0432.CCR-07-4175
P407
P577
2008-01-01T00:00:00Z